BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168:609-616. [PMID: 22985451 DOI: 10.1111/bjd.12045] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Puig L, Carrascosa J, Carretero G, de la Cueva P, Lafuente-urrez R, Belinchón I, Sánchez-regaña M, García-bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-patos V, Herrera E, Estebaranz JL, Marrón S, Moreno J, Notario J, Rivera R, Rodriguez-cerdeira C, Romero A, Ruiz-villaverde R, Taberner R, Vidal D. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento. Actas Dermo-Sifiliográficas 2013;104:694-709. [DOI: 10.1016/j.ad.2013.04.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
2 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
3 López-Serrano P, de la Fuente Briongos E, Alonso EC, Pérez-Calle JL, Rodríguez CF. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539-547. [PMID: 25848477 DOI: 10.4254/wjh.v7.i3.539] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 AlMutairi N, Abouzaid HA. Safety of biologic agents for psoriasis in patients with viral hepatitis. J Dermatolog Treat 2018;29:553-6. [PMID: 29345515 DOI: 10.1080/09546634.2018.1430301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
6 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
7 Morisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol 2014;14:214. [PMID: 25523080 DOI: 10.1186/s12876-014-0214-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
8 Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal of the American Academy of Dermatology 2017;77:88-97.e5. [DOI: 10.1016/j.jaad.2017.01.037] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
9 Chat VS, Uppal SK, Kearns DG, Wu JJ. Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: A critical appraisal and comprehensive review. Dermatol Ther 2021;34:e14974. [PMID: 33991048 DOI: 10.1111/dth.14974] [Reference Citation Analysis]
10 Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015;73:420-428.e1. [PMID: 26184440 DOI: 10.1016/j.jaad.2015.06.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
11 Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol 2018;19:1-13. [PMID: 29080066 DOI: 10.1007/s40257-017-0328-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 10.3] [Reference Citation Analysis]
12 Piaserico S, Conti A, Coati I, Galdo G, Bernabucci V, Zanca A, Drabeni M, Masutti F, Musumeci ML, Alberti A, Russo FP. Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. G Ital Dermatol Venereol 2019;154. [DOI: 10.23736/s0392-0488.17.05487-6] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244. e3. [PMID: 25447852 DOI: 10.1053/j.gastro.2014.10.038] [Cited by in Crossref: 274] [Cited by in F6Publishing: 231] [Article Influence: 39.1] [Reference Citation Analysis]
14 Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72. [PMID: 30772098 DOI: 10.1016/j.jaad.2018.11.057] [Cited by in Crossref: 197] [Cited by in F6Publishing: 138] [Article Influence: 98.5] [Reference Citation Analysis]
15 Warren RB, Al-Rifai A. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C. Br J Dermatol. 2013;168:461-462. [PMID: 23445306 DOI: 10.1111/bjd.12227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
17 Carrascosa JM, Del-alcazar E. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert Review of Clinical Immunology 2018;14:259-73. [DOI: 10.1080/1744666x.2018.1454835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017;9:613-26. [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
19 Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021;27:2312-24. [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] [Reference Citation Analysis]
20 Ting SW, Chen YC, Huang YH. Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab. Clin Drug Investig. 2018;38:873-880. [PMID: 29968197 DOI: 10.1007/s40261-018-0671-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
21 Ara M, Daudén E. Etanercept for the treatment of psoriasis. Expert Review of Dermatology 2014;8:357-72. [DOI: 10.1586/17469872.2013.814880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
22 Hamadah IR, Al Raddadi AA, Bahamdan KA, Fatani MI, Alnahdi A, Al Rakban AM, Alkhalifah A, Al Ameer A, Shaikh YH, Elgendi AM, Al Zoman AY, Alafif KA. Saudi practical guidelines on biologic treatment of psoriasis. J Dermatolog Treat 2015;26:223-9. [PMID: 25075955 DOI: 10.3109/09546634.2014.946882] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
23 Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2016;30 Suppl 2:1-18. [PMID: 26812550 DOI: 10.1111/jdv.13542] [Cited by in Crossref: 66] [Cited by in F6Publishing: 36] [Article Influence: 13.2] [Reference Citation Analysis]
24 Zabotti A, Goletti D, Lubrano E, Cantini F. The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. Expert Opin Drug Saf 2020;19:69-82. [PMID: 31847608 DOI: 10.1080/14740338.2020.1703946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015;7:825-30. [PMID: 25937860 DOI: 10.4254/wjh.v7.i6.825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
27 Rosales Santillan M, Morss PC, Porter ML, Kimball AB. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 2020;20:621-33. [PMID: 32077334 DOI: 10.1080/14712598.2020.1732918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853-1859. [PMID: 28146345 DOI: 10.1111/jdv.14146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
29 Chiu HY, Chiu YM, Chang Liao NF, Chi CC, Tsai TF, Hsieh CY, Hsieh TY, Lai KL, Chiu TM, Wu NL, Hui RC, Lee CN, Wang TS, Chen PH, Yang CC, Huang YH. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biological agent: A nine-year multicenter cohort study. J Am Acad Dermatol. 2019;. [PMID: 31821860 DOI: 10.1016/j.jaad.2019.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Guillot B. Quoi de neuf en thérapeutique dermatologique ? Annales de Dermatologie et de Vénéréologie 2013;140:S293-302. [DOI: 10.1016/s0151-9638(13)70145-5] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 2019;80:43-53. [DOI: 10.1016/j.jaad.2018.06.056] [Cited by in Crossref: 119] [Cited by in F6Publishing: 83] [Article Influence: 59.5] [Reference Citation Analysis]
32 Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19:7867-7873. [PMID: 24307780 DOI: 10.3748/wjg.v19.i44.7867] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
33 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
34 Plachouri KM, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73. [PMID: 30428753 DOI: 10.1080/09546634.2018.1544413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Damiani G, Franchi C, Pigatto P, Altomare A, Pacifico A, Petrou S, Leone S, Pace MC, Fiore M. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents. World J Hepatol 2018;10:329-36. [PMID: 29527268 DOI: 10.4254/wjh.v10.i2.329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
36 Sanz-Bueno J, Vanaclocha F, García-Doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-Genao D, Alsina-Gibert MM, Pérez-Zafrilla B, Pérez-Rial G. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Actas Dermosifiliogr. 2015;106:477-482. [PMID: 25776200 DOI: 10.1016/j.ad.2015.01.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
37 Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295-1303. [PMID: 23746170 DOI: 10.1111/bjd.12461] [Cited by in Crossref: 87] [Cited by in F6Publishing: 68] [Article Influence: 12.4] [Reference Citation Analysis]
38 Cetkovska P, Lomicova I, Mukensnabl P, Kroes AC. Anti-tumour necrosis factor treatment of severe psoriasis complicated by Epstein-Barr Virus hepatitis and subsequently by chronic hepatitis. Dermatol Ther 2015;28:369-72. [PMID: 26278774 DOI: 10.1111/dth.12271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Parker S, Zhang CS, Yu JJ, Lu C, Zhang AL, Xue CC. Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review. J Dermatolog Treat 2017;28:21-31. [PMID: 27366921 DOI: 10.1080/09546634.2016.1178377] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
40 Siegel S, Winthrop K, Ehst B, Ortega Loayza A. Ustekinumab use in patients with severe psoriasis co‐infected with hepatitis B and/or C. Br J Dermatol 2019;180:1232-3. [DOI: 10.1111/bjd.17444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Cantini F, Boccia S, Goletti D, Iannone F, Leoncini E, Panic N, Prignano F, Gaeta GB. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol 2014;2014:926836. [PMID: 25114684 DOI: 10.1155/2014/926836] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
42 Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22:6444-6455. [PMID: 27605880 DOI: 10.3748/wjg.v22.i28.6444] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
43 Koutsianas C, Thomas K, Vassilopoulos D. Prevention of HBV reactivation in patients treated with biologic agents. Expert Rev Clin Pharmacol. 2016; Epub ahead of print. [PMID: 26775683 DOI: 10.1586/17512433.2016.1143773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
44 Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis (Auckl) 2017;7:35-40. [PMID: 29387606 DOI: 10.2147/PTT.S108209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Martinez-Santana V, Rodriguez-Murphy E, Smithson A, Miserachs-Aranda N, Del Río-Gil R, Torre-Lloverás I. Efficacy and safety of direct-acting antiviral agents when combined with secukinumab. Eur J Hosp Pharm 2018;25:53-6. [PMID: 31156986 DOI: 10.1136/ejhpharm-2017-001212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
47 Puig L, Carrascosa J, Carretero G, de la Cueva P, Lafuente-urrez R, Belinchón I, Sánchez-regaña M, García-bustínduy M, Ribera M, Alsina M, Ferrándiz C, Fonseca E, García-patos V, Herrera E, López-estebaranz J, Marrón S, Moreno J, Notario J, Rivera R, Rodriguez-cerdeira C, Romero A, Ruiz-villaverde R, Taberner R, Vidal D. Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. Actas Dermo-Sifiliográficas (English Edition) 2013;104:694-709. [DOI: 10.1016/j.adengl.2013.04.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Sanz-bueno J, Vanaclocha F, García-doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-genao D, Alsina-gibert M, Pérez-zafrilla B, Pérez-rial G, Rivera R. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Actas Dermo-Sifiliográficas (English Edition) 2015;106:477-82. [DOI: 10.1016/j.adengl.2015.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Llamas-Velasco M, Concha-Garzón MJ, García-Diez A, Daudén E. Liver Injury in Psoriasis Patients Receiving Ustekinumab: A Retrospective Study of 44 Patients Treated in the Clinical Practice Setting. Actas Dermosifiliogr 2015;106:470-6. [PMID: 25912374 DOI: 10.1016/j.ad.2015.02.002] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
50 Viganò M, Serra G, Casella G, Grossi G, Lampertico P. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 2016;16:917-26. [PMID: 27088278 DOI: 10.1080/14712598.2016.1177017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
51 Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70:178-186. [PMID: 24220724 DOI: 10.1016/j.jaad.2013.08.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]